Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi1, Suma Pusapati1, Muhammad Saad Anwar1
1The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Frontiers in Immunology
|June 2, 2023
Summary
Glucagon-like peptide-1 (GLP-1) is a newly recognized anti-inflammatory peptide. This review explores GLP-1
Area of Science:
- Immunology
- Endocrinology
- Metabolic Diseases
Background:
- Inflammation, characterized by pro-inflammatory cytokines and immune cells, underlies many chronic diseases.
- Glucagon-like peptide-1 (GLP-1) levels correlate with disease severity and can indicate inflammation.
- While other peptides like oxytocin and ACTH have known anti-inflammatory roles, GLP-1's are recently recognized.
Purpose of the Study:
- To review the emerging understanding of Glucagon-like peptide-1 (GLP-1) as an anti-inflammatory agent.
- To explore the connection between GLP-1, inflammation, and sepsis.
Main Methods:
- Literature review of existing studies on GLP-1, inflammation, and related conditions.
- Analysis of the role of GLP-1 in modulating inflammatory pathways.
- Examination of GLP-1's therapeutic potential in inflammatory diseases.
Main Results:
- GLP-1 exhibits receptor-mediated anti-inflammatory properties, protecting cells from damage and apoptosis.
- GLP-1 has demonstrated efficacy as an adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia.
- GLP-1 reduces HbA1C and offers cardiovascular and nervous system protection by mitigating inflammation.
Conclusions:
- GLP-1 represents a significant, recently identified player in the body's inflammatory response.
- GLP-1's anti-inflammatory actions suggest its potential as a therapeutic target for various inflammatory conditions, including sepsis.
- Further research into GLP-1's mechanisms and applications in inflammation is warranted.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
220
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
220
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
01:16Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K